McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia

Orphanet Journal of Rare Diseases

Volumn 7, Issue SUPPL. 1, 2012, Pages

  Collins, Michael T ^a   Singer, Frederick R ^b   Eugster, Erica ^c  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b JOHN WAYNE CANCER INSTITUTE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; ANASTROZOLE; BICALUTAMIDE; CALCITRIOL; CYPROTERONE ACETATE; FADROZOLE; FLUTAMIDE; GONADOTROPIN; GROWTH HORMONE; KETOCONAZOLE; LETROZOLE; LIOTHYRONINE; MEDRONATE TECHNETIUM TC 99M; METYRAPONE; PHOSPHATE; SOMATOMEDIN C; SPIRONOLACTONE; TAMOXIFEN; TESTOLACTONE; THIONAMIDE; THYROXINE; VITAMIN D; AROMATASE INHIBITOR; GNAS PROTEIN, HUMAN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ALBRIGHT SYNDROME; BARRETT ESOPHAGUS; BONE SCINTISCANNING; BREAST CANCER; BREAST DEVELOPMENT; CAFE AU LAIT SPOT; CHONDROSARCOMA; CLINICAL FEATURE; COGNITIVE DEFECT; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CUSHING SYNDROME; DILATATION; DRUG DOSE INCREASE; DRUG EFFICACY; FIBROSARCOMA; FIBROUS DYSPLASIA; FOLLOW UP; GASTROINTESTINAL REFLUX; GASTRULATION; GENE MUTATION; HIGH OUTPUT HEART FAILURE; HUMAN; HYPERPROLACTINEMIA; HYPERTHYROIDISM; HYPOPHOSPHATEMIA; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; LEARNING DISORDER; LUNG CANCER; MESENCHYMOMA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; OSTEOSARCOMA; PANCREATITIS; PHYSICAL EXAMINATION; PRECOCIOUS PUBERTY; PREVALENCE; PROGNOSIS; SPEECH DISORDER; STOMACH POLYP; SUDDEN DEATH; TACHYCARDIA; TESTIS CANCER; THROMBOCYTE DYSFUNCTION; THYROID CANCER; ULTRASOUND; VAGINA BLEEDING; WASTING SYNDROME; ACROMEGALY; COHORT ANALYSIS; GENETICS; GROWTH HORMONE EXCESS; MUTATION; REVIEW;

ACROMEGALY; AROMATASE INHIBITORS; CAFE-AU-LAIT SPOTS; COHORT STUDIES; CUSHING SYNDROME; FIBROUS DYSPLASIA OF BONE; FIBROUS DYSPLASIA, POLYOSTOTIC; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; HYPERTHYROIDISM; HYPOPHOSPHATEMIA; MUTATION; PHYSICAL EXAMINATION; PUBERTY, PRECOCIOUS;

EID: 84861361722     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-7-S1-S4     Document Type: Conference Paper

References (70)

1. Osteitis fibrosa cystica; the case of a nine year old girl who also exhibits precocious puberty, multiple pigmentation of the skin and hyperthyroidism. McCune DJ, Am J Dis Child 1936 52 743 744
2. Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females, report of five cases. Albright F, Butler AM, Hampton AO, Smith PH, N Engl J Med 1937 216 727 746 10.1056/NEJM193704292161701
3. Atypical McCune-Albright syndrome associated with growth hormone-prolactin pituitary adenoma: natural history, long-term follow-up, and SMS 201-995 - Bromocriptine combined treatment results. Cremonini N, Graziano E, Chiarini V, Sforza A, Zampa GA, J Clin Endocrinol Metab 1992 75 1166 1169 10.1210/jc.75.4.1166 1400888
4. Polyostotic fibrous dysplasia associated with Cushing syndrome. Benjamin DR, McRoberts JW, Arch Pathol 1973 96 175 178 4722878
5. Fibrous dysplasia of bone with vitamin D resistant rickets: a case study. Ryan WG, Nibbe AF, Schwartz TB, Ray RD, Metabolism 1968 17 988 998 10.1016/0026-0495(68)90004-8 5724172
6. Demonstration of McCune-Albright mutations in the liver of children with high gammaGT progressive cholestasis. Silva ES, Lumbroso S, Medina M, Gillerot Y, Sultan C, Sokal EM, J Hepatol 2000 32 154 158 10673080 (Pubitemid 30039460)
7. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM, N Engl J Med 1991 325 1688 1695 10.1056/NEJM199112123252403 1944469
8. McCune-Albright syndrome. Dumitrescu CE, Collins MT, Orphanet J Rare Dis 2008 3 12 10.1186/1750-1172-3-12 18489744
9. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM, N Engl J Med 1991 325 1688 1695 10.1056/NEJM199112123252403 1944469
10. Identification of a mutation in the gene encoding the a subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Schwindinger WF, Francomano CA, Levine MA, Proc Natl Acad Sci USA 1992 89 5152 5156 10.1073/pnas.89.11.5152 1594625
11. Activating mutation of Gsa in McCune-Albright syndrome causes skin pigmentation by tyrosinase gene activation on affected melanocytes. Kim I, Kim ER, Nam HJ, Chin MO, Moon YH, Oh MR, Yeo UC, Song SM, Kim JS, Uhm MR, Beck NS, Jin DK, Horm Res 1999 52 235 240 10.1159/000023467 10844413 (Pubitemid 30303716)
12. Long-term follow-up of a case of cheek hyperpigmentation associated with McCune-Albright syndrome treated with Q-switched ruby laser. Ozawa T, Tateishi C, Shirakawa M, Murakami E, Ishii M, Harada T, Dermatol Surg 2011 37 263 266 10.1111/j.1524-4725.2010.01864.x 21272121
13. The role of type-1 and type-2 5'deiodinase in the pathophysiology of the T3 toxicosis of McCune-Albright syndrome. Celi FS, Coppotelli G, Chidakel A, Kelly M, Brillante BA, Shawker T, Cherman N, Feuillan PP, Collins MT, J Clin Endocrinol Metab 2008 93 2383 2389 10.1210/jc.2007-2237 18349068 (Pubitemid 351831562)
14. Alteration in cyclic AMP-dependent protein kinases and polyamine biosynthetic enzymes during hypertrophy and hyperplasia of the thyroid in the rat. Combest WL, Russell DH, Mol Pharmacol 1983 23 641 647 6306431 (Pubitemid 13089781)
15. Thyroid abnormalities in the McCune-Albright syndrome: ultrasonography and hormone studies. Feuillan PP, Shawker T, Rose SR, Jones J, Jeevanram RK, Nisula BC, J Clin Endocrinol Metab 1990 71 1596 1601 10.1210/jcem-71-6-1596 2229316 (Pubitemid 120032781)
16. Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. Collins MT, Chebli C, Jones J, Kushner H, Consugar M, Rinaldo P, Wientroub S, Bianco P, Robey PG, J Bone Miner Res 2001 16 806 813 10.1359/jbmr.2001.16.5.806 11341325 (Pubitemid 32332290)
17. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P, J Clin Invest 2003 112 683 692 12952917 (Pubitemid 38057709)
18. Age-dependent demise of GNAS-mutated skeletal stem cells and "normalization" of fibrous dysplasia of bone. Kuznetsov SA, Cherman N, Riminucci M, Collins MT, Robey PG, Bianco P, J Bone Miner Res 2008 23 1731 1740 10.1359/jbmr.080609 18597624
19. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. Leet AI, Chebli C, Kushner H, Chen CC, Kelly MH, Brillante BA, Robey PG, Bianco P, Wientroub S, Collins MT, J Bone Miner Res 2004 19 571 577 15005844 (Pubitemid 41071217)
20. A clinician's guide to X-linked hypophosphatemia. Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL, J Bone Miner Res 2011 26 1381 1388 DOI: 10.1002/jbmr.340 10.1002/jbmr.340 21538511
21. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D, Cherman N, Bianco P, Wientroub S, Robey PG, Collins MT, J Clin Endocrinol Metab 2002 87 5104 5112 10.1210/jc.2001-012022 12414879 (Pubitemid 35316352)
22. Normal vision despite narrowing of the optic canal in fibrous dysplasia. Lee JS, FitzGibbon E, Butman JA, Dufresne CR, Kushner H, Wientroub S, Robey PG, Collins MT, N Engl J Med 2002 347 1670 1676 10.1056/NEJMoa020742 12444181 (Pubitemid 35340785)
23. Long-term outcome of optic nerve encasement and optic nerve decompression in patients with fibrous dysplasia: risk factors for blindness and safety of observation. Cutler CM, Lee JS, Butman JA, FitzGibbon EJ, Kelly MH, Brillante BA, Feuillan P, Robey PG, DuFresne CR, Collins MT, Neurosurgery 2006 59 1011 1017 discussion 1017-1018 17143235 (Pubitemid 44852072)
24. Growth hormone suppression after an oral glucose load in children. Misra M, Cord J, Prabhakaran R, Miller KK, Klibanski A, J Clin Endocrinol Metab 2007 92 4623 4629 10.1210/jc.2007-1244 17878248 (Pubitemid 350223436)
25. Malignancies in fibrous dysplasia. Ruggieri P, Sim FH, Bond JR, Unni KK, Cancer 1994 73 1411 1424 10.1002/1097-0142(19940301)73:5<1411::AID- CNCR2820730516>3.0.CO;2-T 8111708 (Pubitemid 24072547)
26. A case of McCune-Albright syndrome associated with pituitary GH adenoma: therapeutic process and autopsy. Liu F, Li W, Yao Y, Li G, Yang Y, Dou W, Zhong D, Wang L, Zhu X, Hu H, Zhang J, Wang R, Chen G, J Pediatr Endocrinol Metab 2011 24 283 287 21823524
27. Treatment of acromegaly with a somatostatin analog in a patient with McCune-Albright syndrome. Geffner ME, Nagel RA, Dietrich RB, Kaplan SA, J Pediatr 1987 111 740 743 10.1016/S0022-3476(87)80258-5 2889819 (Pubitemid 18017907)
28. McCune-Albright syndrome: growth hormone and prolactin hypersecretion. Christoforidis A, Maniadaki I, Stanhope R, J Pediatr Endocrinol Metab 2006 19 Suppl 2 623 625 16789626
29. Growth hormone hypersecretion in a girl with McCune-Albright syndrome: comparison with controls and response to a dose of long-acting somatostatin analog. Feuillan PP, Jones J, Ross JL, J Clin Endocrinol Metab 1995 80 1357 1360 10.1210/jc.80.4.1357 7714111
30. McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients. Galland F, Kamenicky P, Affres H, Reznik Y, Pontvert D, Le Bouc Y, Young J, Chanson P, J Clin Endocrinol Metab 2006 91 4957 4961 DOI: 10.1210/jc.2006-0561 10.1210/jc.2006-0561 16984995 (Pubitemid 44917334)
31. Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome. Akintoye SO, Kelly MH, Brillante B, Cherman N, Turner S, Butman JA, Robey PG, Collins MT, J Clin Endocrinol Metab 2006 91 2960 2966 DOI: 10.1210/jc.2005-2661 10.1210/jc.2005-2661 16720661 (Pubitemid 44271742)
32. Cushing syndrome in the McCune-Albright syndrome. Brown RJ, Kelly MH, Collins MT, J Clin Endocrinol Metab 2010 95 1508 1515 10.1210/jc.2009-2321 20157193
33. Primary bimorphic adrenocortical disease: cause of hypercortisolism in McCune-Albright syndrome. Carney JA, Young WF, Stratakis CA, Am J Surg Pathol 2011 35 1311 1326 DOI: 10.1097/PAS.0b013e31821ec4ce 10.1097/PAS.0b013e31821ec4ce 21836496
34. Cushing's syndrome caused by nodular adrenal hyperplasia in children with McCune-Albright syndrome. Kirk JM, Brain CE, Carson DJ, Hyde JC, Grant DB, J Pediatr 1999 134 789 792 10.1016/S0022-3476(99)70302-1 10356155 (Pubitemid 30186830)
35. The genomic landscapes of human breast and colorectal cancers. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B, Science 2007 318 1108 1113 10.1126/science.1145720 17932254 (Pubitemid 350134889)
36. The McCune-Albright syndrome. Mauras N, Blizzard RM, Acta Endocrinol Suppl (Copenh) 1986 279 207 217 3465162 (Pubitemid 17170000)
37. Acromegaly and cardiovascular disorders. A prospective study. McGuffin WL Jr, Sherman BM, Roth F, Gorden P, Kahn CR, Roberts WC, Frommer PL, Ann Intern Med 1974 81 11 18 4276173
38. Platelet dysfunction and increased bleeding tendency in McCune-Albright syndrome. Bajpai A, Greenway A, Zacharin M, J Pediatr 2008 153 287 289 10.1016/j.jpeds.2008.02.045 18639732 (Pubitemid 351970568)
39. s and stimulate adenylyl cyclase in human pituitary tumours. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L, Nature 1989 340 692 696 10.1038/340692a0 2549426 (Pubitemid 19214389)
40. Establishment and characterization of a cell line from a malignant fibrous histiocytoma of bone developing in a patient with multiple fibrous dysplasia. Fang Z, Mukai H, Nomura K, Shinomiya K, Matsumoto S, Kawaguchi N, Kitagawa T, Kanda H, J Cancer Res Clin Oncol 2002 128 45 49 10.1007/s00432-001- 0295-0 11862471 (Pubitemid 34151121)
41. Fibrous dysplasia with cartilaginous differentiation (" fibrocartilaginous dysplasia"): a review, with an illustrative case followed for 18 years. Kyriakos M, McDonald DJ, Sundaram M, Skeletal Radiol 2004 33 51 62 10.1007/s00256-003-0718-x 14647989 (Pubitemid 38111316)
42. Dedifferentiated chondrosarcoma in Albright syndrome. A case report and review of the literature. Ozaki T, Lindner N, Blasius S, J Bone Joint Surg Am 1997 79 1545 1551 9378741 (Pubitemid 27459301)
43. Fibrous dysplasia of the spine with sarcomatous transformation: a case report and review of the literature. Yalniz E, Er T, Ozyilmaz F, Eur Spine J 1995 4 372 374 10.1007/BF00300303 8983661
44. Maxillary malignant mesenchymoma and massive fibrous dysplasia. Beuerlein ME, Schuller DE, DeYoung BR, Arch Otolaryngol Head Neck Surg 1997 123 106 109 10.1001/archotol.1997.01900010116019 9006514 (Pubitemid 27043669)
45. Malignant change secondary to fibrous dysplasia. Hoshi M, Matsumoto S, Manabe J, Tanizawa T, Shigemitsu T, Izawa N, Takeuchi K, Kawaguchi N, Int J Clin Oncol 2006 11 229 235 10.1007/s10147-006-0559-4 16850130 (Pubitemid 44087122)
46. Malignancies in fibrous dysplasia. Ruggieri P, Sim FH, Bond JR, Unni KK, Cancer 1994 73 1411 1424 10.1002/1097-0142(19940301)73:5<1411::AID- CNCR2820730516>3.0.CO;2-T 8111708 (Pubitemid 24072547)
47. Osteosarcoma in a pregnant patient with McCune-Albright syndrome. Kanazawa I, Yamauchi M, Yano S, Imanishi Y, Kitazawa R, Nariai Y, Araki A, Kobayashi K, Inaba M, Maruyama R, Yamaguchi T, Sugimoto T, Bone 2009 45 603 608 DOI: 10.1016/j.bone.2009.05.018 10.1016/j.bone.2009.05.018 19481621
48. Chondrosarcoma in a patient with McCune-Albright syndrome. Report of a case. Blanco P, Schaeverbeke T, Baillet L, Lequen L, Bannwarth B, Dehais J, Rev Rhum Engl Ed 1999 66 177 179 10327499 (Pubitemid 29156814)
49. McCune-Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases. Chanson P, Dib A, Visot A, Derome PJ, Eur J Endocrinol 1994 131 229 234 10.1530/eje.0.1310229 7921205 (Pubitemid 24297510)
50. Osteosarcoma of the mandible arising in fibrous dysplasia. A case report. Present D, Bertoni F, Enneking WF, Clin Orthop Relat Res 1986 238 244 3456857 (Pubitemid 16069380)
51. Osteosarcoma and acromegaly: a case report and review of the literature. Lima GA, Gomes EM, Nunes RC, Vieira Neto L, Sieiro AP, Brabo EP, Gadelha MR, J Endocrinol Invest 2006 29 1006 1011 17259799 (Pubitemid 46344236)
52. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, Ekbom A, Olsen JH, Baron JA, Fraumeni JF Jr, Cancer Causes Control 2002 13 395 400 10.1023/A:1015713732717 12146843 (Pubitemid 34666594)
53. Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. Collins MT, Sarlis NJ, Merino MJ, Monroe J, Crawford SE, Krakoff JA, Guthrie LC, Bonat S, Robey PG, Shenker A, J Clin Endocrinol Metab 2003 88 4413 4417 10.1210/jc.2002-021642 12970318 (Pubitemid 37153751)
54. Breast cancer in a patient with McCune-Albright syndrome. Tanabeu Y, Nakahara S, Mitsuyama S, Ono M, Toyoshima S, Breast Cancer 1998 25 175 178 11091644
55. Ductal carcinoma in situ in a 27-year-old woman with McCune-Albright syndrome. Huston TL, Simmons RM, Breast J 2004 10 440 442 10.1111/j.1075-122X. 2004.21490.x 15327499 (Pubitemid 39281318)
56. Cancers associated with acromegaly. Jenkins PJ, Neuroendocrinology 2006 83 218 223 10.1159/000095531 17047386 (Pubitemid 44578875)
57. Severe hyperparathyroidism associated with fibrous dysplasia: a case report. Arik N, Biriken D, Akpolat T, Sungur C, Coskun C, Basoglu T, Keskin M, Sahin M, Toller MO, Nephron 1996 74 481 482 10.1159/000189380 8893201 (Pubitemid 26326747)
58. Craniofacial fibrous dysplasia associated with primary hyperparathyroidism. Braccini F, Bacciu A, Bruzzo M, Pech-Gourg F, Thomassin JM, Acta Biomed Ateneo Parmense 1999 70 5 11 11402810
59. Possible relationship of primary hyperparathyroidism and fibrous dysplasia: report of case. Caudill R, Saltzman D, Gaum S, Granite E, J Oral Surg 1977 35 483 490 266063 (Pubitemid 8121699)
60. McCune-Albright syndrome: how many endocrinopathies can one patient have? Cavanah SF, Dons RF, South Med J 1993 86 364 367 8451681 (Pubitemid 23091263)
61. Fibrous dysplasia of bone and primary hyperparathyroidism. Ehrig U, Wilson DR, Ann Intern Med 1972 77 234 238 4641656
62. Primary hyperparathyroidism-associated polyostotic fibrous dysplasia: absence of McCune-Albright syndrome mutations. Hammami MM, al-Zahrani A, Butt A, Vencer LJ, Hussain SS, J Endocrinol Invest 1997 20 552 558 9413810 (Pubitemid 28014508)
63. Endocrine features in Albright's syndrome (fibrous dysplasia of bone). Benedict PH, Metabolism 1962 11 30 45 13867139
64. Chronic Galphas signaling in the striatum increases anxiety-related behaviors independent of developmental effects. Favilla C, Abel T, Kelly MP, J Neurosci 2008 28 13952 13956 10.1523/JNEUROSCI.4986-08.2008 19091983
65. Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia. Kelly MP, Stein JM, Vecsey CG, Favilla C, Yang X, Bizily SF, Esposito MF, Wand G, Kanes SJ, Abel T, Molecular psychiatry 2009 14 398 415 347 10.1038/mp.2008.124 19030002
66. Constitutive activation of the G-protein subunit Galphas within forebrain neurons causes PKA-dependent alterations in fear conditioning and cortical Arc mRNA expression. Kelly MP, Cheung YF, Favilla C, Siegel SJ, Kanes SJ, Houslay MD, Abel T, Learning & Memory Cold Spring Harbor, NY 2008 15 75 83 10.1101/lm.723708 22496946 (Pubitemid 351281569)
67. Chronically increased Gsalpha signaling disrupts associative and spatial learning. Bourtchouladze R, Patterson SL, Kelly MP, Kreibich A, Kandel ER, Abel T, Learning & Memory Cold Spring Harbor, NY 2006 13 745 752 10.1101/lm.354106 22496946 (Pubitemid 44871675)
68. Mice expressing constitutively active Gsalpha exhibit stimulus encoding deficits similar to those observed in schizophrenia patients. Maxwell CR, Liang Y, Kelly MP, Kanes SJ, Abel T, Siegel SJ, Neuroscience 2006 141 1257 1264 10.1016/j.neuroscience.2006.04.028 16750890 (Pubitemid 44128661)
69. Constitutive activation of Galphas within forebrain neurons causes deficits in sensorimotor gating because of PKA-dependent decreases in cAMP. Kelly MP, Isiegas C, Cheung YF, Tokarczyk J, Yang X, Esposito MF, Rapoport DA, Fabian SA, Siegel SJ, Wand G, Houslay MD, Kanes SJ, Abel T, Neuropsychopharmacology 2007 32 577 588 10.1038/sj.npp.1301099 16738544
70. Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of Gs alpha. Gould TJ, Bizily SP, Tokarczyk J, Kelly MP, Siegel SJ, Kanes SJ, Abel T, Neuropsychopharmacology 2004 29 494 501 10.1038/sj.npp.1300309 14694347 (Pubitemid 38365925)